LOW-DOSE CYCLOSPORINE-A THERAPY IN PYODERMA GANGRAENOSUM - EXPERIENCE WITH 6 PATIENTS

被引:14
作者
ZUMDICK, M
GOERZ, G
SCHUPPE, HC
MILDE, P
RUZICKA, T
机构
来源
HAUTARZT | 1995年 / 46卷 / 10期
关键词
PYODERMA GANGRAENOSUM; CYCLOSPORINE A;
D O I
10.1007/s001050050324
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Pyoderma gangraenosum can cause great therapeutic problems. High dosed corticosteroids are the treatment of choice. However, recalcitrant pyoderma gangraenosum or side effects from corticosteroid treatment may require therapeutic alternatives. Pyoderma gangraenosum responds excellently to treatment with cyclosporine A, Because of side effects and drug interactions, the patients must he selected and carefully and closely monitored, Six patients with pyoderma gangraenosum unresponsive to various topical and systemic therapies, were treated with oral cyclosporine A at mean daily closes of approximately 3 mg/kg Marked improvement of the skin lesions and complete healing occurred in all patients over a period of 3-6 months. Only one patient suffered a relapse after discontinuation of the treatment, No severe irreversible side effects occurred. The results show that low-dose cyclosporine A treatment can be considered a first-line treatment of pyoderma gangraenosum.
引用
收藏
页码:697 / 701
页数:5
相关论文
共 27 条
[1]   RENAL EFFECTS OF CYCLOSPORINE [J].
BENNETT, WM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 23 (06) :1280-1287
[2]   Pyoderma (echthyma) gangrenosum - Clinical and experimental observations in five cases occurring in adults [J].
Brunsting, LA ;
Goeckerman, WH ;
O'Leary, PA .
ARCHIVES OF DERMATOLOGY AND SYPHILOLOGY, 1930, 22 (04) :655-680
[3]   PYODERMA GANGRENOSUM TREATED WITH CYCLOSPORIN-A [J].
CURLEY, RK ;
MACFARLANE, AW ;
VICKERS, CFH .
BRITISH JOURNAL OF DERMATOLOGY, 1985, 113 (05) :601-604
[4]   TREATMENT OF PYODERMA-GANGRENOSUM WITH CYCLOSPORINE - RESULTS IN 7 PATIENTS [J].
ELGART, G ;
STOVER, P ;
LARSON, K ;
SUTTER, C ;
SCHEIBNER, S ;
DAVIS, B ;
BASS, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (01) :83-86
[5]   RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES [J].
FEUTREN, G ;
MIHATSCH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) :1654-1660
[6]   MANAGEMENT OF PATIENTS AND SIDE-EFFECTS DURING CYCLOSPORINE THERAPY FOR CUTANEOUS DISORDERS [J].
FRADIN, MS ;
ELLIS, CN ;
VOORHEES, JJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 23 (06) :1265-1275
[7]  
FREY FJ, 1990, SCHWEIZ MED WSCHR, V120, P772
[8]  
GRUHL L, 1992, HANDCHIR MIKROCHIR P, V24, P49
[9]   ORAL CYCLOSPORINE IN THE TREATMENT OF INFLAMMATORY AND NONINFLAMMATORY DERMATOSES - A CLINICAL AND IMMUNOPATHOLOGIC ANALYSIS [J].
GUPTA, AK ;
ELLIS, CN ;
NICKOLOFF, BJ ;
GOLDFARB, MT ;
HO, VC ;
ROCHER, LL ;
GRIFFITHS, CEM ;
COOPER, KD ;
VOORHEES, JJ .
ARCHIVES OF DERMATOLOGY, 1990, 126 (03) :339-350
[10]  
HELLER PE, 1986, J AM ACAD DERMATOL, V14, P785